MARATTO

article · Journal of the American Society of Nephrology

Clinical Features and Outcomes of Pregnancy-Related AKI: A Single Tertiary Center Study

Abstract

Background: Pregnancy-related acute kidney injury (Pr-AKI) is a major cause of maternal and fetal morbidity and mortality in developing countries. The aim of our study was to study the clinical characteristics and outcomes of patients with Pr-AKI at our center. Methods: This prospective study at Zagazig University Hospital, Egypt, from October 1, 2023, to March 1, 2024, included patients with post-partum AKI. These women were compared to a matched cohort of healthy pregnant women without pre-existing AKI.Multivariate analysis is used to identify risk factors. Results: Out of 900 pregnant patients who delivered during the study period, 52 patients developed post-partum AKI with incident of 5.7%. The majority were multiparous( 59.6%), and most delivered by cesarean section (67.3%).The most common cause of AKI is preeclampsia (51.9%) , followed by ante-partum hemorrhage (40.4%) and HEELP syndrome (36.5%). Stage 3 AKI (KDIGO classification) was the most prevalent occurring in 23% of cases. Maternal death occurred in 13.5% of cases, while fetal death was 17.3%. Follow- up showed that 42.3% had complete recovery, 30.7% CKD and 13.4% remained dialysis-dependent. Risk factors for AKI included high WBC, low Hb, low platelets, and high bilirubin levels, with p-values of 0.004, <0.0001, and 0.031, respectively. Additionally, nulliparous women had significantly lower odds of developing AKI (0.248, p = 0.017). However, the significance of these risk factors disappeared in multivariate analysis. Conclusion: Post-partum AKI is a relatively common pregnancy complication with significant maternal and fetal mortality risks. Preeclampsia and ante-partum hemorrhage are major risk factors. Larger, long-term follow-up studies are recommended to confirm these findings. Funding: Private Foundation Support

Research topics

  • Cardiovascular Issues in Pregnancy
  • Pregnancy and Medication Impact

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1681/asn.20241y54b2jm

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.